ERBB2 and breast carcinoma: Such analysis by bioinformatics showed that there was a correlation between PARP1 and BRCA1/2, and at the same time, with ESR1 in the HER2 subgroup; those breast cancer patients can receive not only PARP inhibitors, but also tamoxifen or other drugs for positive ESR1 patients as therapeutic drugs.